SERAFINI, MARTA
 Distribuzione geografica
Continente #
EU - Europa 826
NA - Nord America 642
AS - Asia 205
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.674
Nazione #
US - Stati Uniti d'America 637
IE - Irlanda 247
IT - Italia 217
SE - Svezia 137
DE - Germania 107
CN - Cina 54
UA - Ucraina 54
HK - Hong Kong 34
TR - Turchia 31
IN - India 30
SG - Singapore 27
GB - Regno Unito 24
IR - Iran 19
FI - Finlandia 13
FR - Francia 8
BE - Belgio 7
JP - Giappone 7
CZ - Repubblica Ceca 6
CA - Canada 5
RU - Federazione Russa 3
AT - Austria 2
EU - Europa 1
JO - Giordania 1
KR - Corea 1
RO - Romania 1
VN - Vietnam 1
Totale 1.674
Città #
Dublin 247
Jacksonville 99
Dearborn 56
Chandler 54
Ann Arbor 44
Piemonte 39
Hong Kong 34
Wilmington 33
Lawrence 25
Princeton 25
Bremen 23
San Mateo 22
Ankara 19
Munich 16
Turin 16
Beijing 14
Singapore 14
Zola Predosa 14
Helsinki 13
Ashburn 12
Dallas 12
Kocaeli 11
Hefei 9
Norwalk 8
Andover 7
Brussels 7
Calvisano 7
Novara 7
Seattle 7
Ardabil 6
Brno 6
Milan 6
Woodbridge 5
Bari 4
Biella 4
Cagliari 4
Fairfield 4
Houston 4
Mülheim 4
Shenyang 4
Toronto 4
Zanjan 4
Berlin 3
Boardman 3
Busto Arsizio 3
Cassano Magnago 3
Des Moines 3
Ipswich 3
Monmouth Junction 3
Noicattaro 3
Vercelli 3
Augusta 2
Barzago 2
Cameriano 2
Chengdu 2
Chongqing 2
Como 2
Genova 2
Grafing 2
Guangzhou 2
Gunzenhausen 2
Jinan 2
Leawood 2
Moncalieri 2
Nanchang 2
Napoli 2
Rankweil 2
San Francisco 2
Torino 2
Trieste 2
Vergiate 2
Wenzhou 2
Aachen 1
Aiello del Sabato 1
Alessandria 1
Altavilla Monferrato 1
Amman 1
Bologna 1
Cambridge 1
Caravaggio 1
Catania 1
Cesano Maderno 1
Chiavari 1
Emeryville 1
Falkenstein 1
Finale Emilia 1
Fuzhou 1
Hebei 1
Ho Chi Minh City 1
Horia 1
Huzhou 1
Kecioeren 1
Lissone 1
London 1
Messina 1
Modena 1
Montesarchio 1
Mountain View 1
Nanjing 1
Nizhniy Novgorod 1
Totale 1.050
Nome #
Targeting Transient Receptor Potential Vanilloid 1 (TRPV1) Channel Softly: The Discovery of Passerini Adducts as a Topical Treatment for Inflammatory Skin Disorders 88
Drug Discovery for Soft Drugs on TRPV1 and TRPM8 Channels Using the Passerini Reaction 87
Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity 83
Synthesis, biological evaluation and molecular docking of Ugi and Passerini products as novel indoleamine 2,3-dioxygenase 1 inhibitors 80
Identification of a Potent Phosphoinositide 3-Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs 78
A primer of deuterium in drug design 77
Pyrtriazoles, a Novel Class of Store-Operated Calcium Entry Modulators: Discovery, Biological Profiling, and in Vivo Proof-of-Concept Efficacy in Acute Pancreatitis 75
A multicomponent approach in the discovery of indoleamine 2,3-dioxygenase 1 inhibitors: Synthesis, biological investigation and docking studies 74
Discovery and development of small molecules targeting IDO1 and SOCE 71
Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors 71
Applications of deuterium in medicinal chemistry 69
The Essential Medicinal Chemistry of Essential Medicines 68
An aryne-based three-component access to α-aroylamino amides 67
SOCE: EMERGE UN NUOVO TARGET TERAPEUTICO DAL “CALCIUM TOOLKIT” DELLA CELLULA 65
A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability 62
Arynes and isocyanides: Two close-knit partners in multicomponent reactions 60
The use of 2-hydroxymethyl benzoic acid as an effective water surrogate in the Passerini reaction: A straightforward access to α-hydroxyamides 57
1,2,4-Oxadiazole-Bearing Pyrazoles as Metabolically Stable Modulators of Store-Operated Calcium Entry 57
Soft drugs for dermatological applications: recent trends 51
Store-Operated Calcium Entry as a Therapeutic Target in Acute Pancreatitis: Discovery and Development of Drug-Like SOCE Inhibitors 50
The 115 Year Old Multicomponent Bargellini Reaction: Perspectives and New Applications 48
Tritylamine as an ammonia surrogate in the ugi reaction provides access to unprecedented 5-sulfamido oxazoles using burgess-type reagents 45
What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications 40
The [1,2,4]Triazolo[4,3-a]pyridine as a New Player in the Field of IDO1 Catalytic Holo-Inhibitors 40
A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs 39
Click 1,2,3-triazoles in drug discovery and development: From the flask to the clinic? 33
An Unexpected Deuterium-Induced Metabolic Switch in Doxophylline 29
CIC-39Na reverses the thrombocytopenia that characterizes tubular aggregate myopathy 28
STIM1 and ORAI1 mutations leading to tubular aggregate myopathies are sensitive to the Store-operated Ca2+-entry modulators CIC-37 and CIC-39 25
Totale 1.717
Categoria #
all - tutte 8.164
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.164


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020282 0 4 25 1 39 45 57 14 19 35 33 10
2020/2021196 18 1 18 2 18 18 26 11 35 21 23 5
2021/2022291 27 12 32 41 11 5 13 6 13 47 26 58
2022/2023631 28 29 42 15 61 54 35 37 273 9 35 13
2023/2024202 19 22 21 8 29 3 43 13 6 1 13 24
2024/202534 12 22 0 0 0 0 0 0 0 0 0 0
Totale 1.717